SNDX Syndax Pharmaceuticals Inc.

9.05
0  0%
Previous Close 9.05
Open
Price To Book 3.58
Market Cap 245,216,800
Shares 27,095,779
Volume 0
Short Ratio
Av. Daily Volume 160,202

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data March 7, 2019 failed to meet endpoints.
Entinostat plus Tecentriq - ENCORE 603
Ovarian cancer
Phase 2 top-line data March 7, 2019 failed to meet endpoints.
Entinostat plus Tecentriq - ENCORE 602
Triple negative breast cancer (TNBC)
Phase 2 updated data to be presented September 24, 2018 did not meet prespecified ORR endpoint.
Entinostat plus Keytruda - ENCORE 601
Recurrent non-small cell lung cancer (NSCLC), colorectal cancer
Phase 3 PFS date did not meet primary endpoint - October 25, 2018. OS next interim analysis due 4Q 2019.
E2112
HR+, HER2- breast cancer
Phase 1 initial data due 2H 2019.
SNDX-6352
Chronic graft versus host disease

Latest News

  1. Syndax to Present at the JMP Securities Life Sciences Conference
  2. Edited Transcript of SNDX earnings conference call or presentation 6-May-19 8:30pm GMT
  3. 5 Stellar Stocks For Under $10
  4. Sirnaomics Appoints Allan L. Shaw as Chief Financial Officer
  5. Have Insiders Been Buying Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares This Year?
  6. Syndax to Present at the UBS Global Healthcare Conference
  7. Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates
  8. Syndax: 1Q Earnings Snapshot
  9. Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update
  10. Syndax to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 6, 2019
  11. Syndax Pharmaceuticals Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2019 Annual Meeting
  12. Syndax Announces $26.2 Million Offering of Common Stock and Warrants
  13. Edited Transcript of SNDX earnings conference call or presentation 7-Mar-19 9:30pm GMT
  14. What Do Analysts Think About Syndax Pharmaceuticals, Inc.’s (NASDAQ:SNDX) Earnings Trend?
  15. Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update
  16. Syndax to Present at the Cowen 39th Annual Health Care Conference
  17. Syndax to Announce Fourth Quarter and Year-end 2018 Financial Results and Host Conference Call and Webcast on March 7, 2019
  18. Syndax Announces Clinical Data from its Entinostat Immuno-oncology Program Selected for Two Oral Presentations at the American Association for Cancer Research Annual Meeting 2019
  19. Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
  20. New Research: Key Drivers of Growth for Cronos Group, Spectrum Brands, Black Hills, Entercom Communications, CSS Industries, and Syndax Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production